Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Latanaprost 0.005% once daily (n=231)
B. Placebo (n=230)

Sample Characteristics

1. N
A. Latanaprost 0.005% once daily (n=231)
B. Placebo (n=230)
Total
2. Baseline population
A. Latanaprost 0.005% once daily (n=231)
B. Placebo (n=230)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
ContinuousQuality of lifeOverall patient-reported quality of life outcomes
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Continuous


Quality of life (Overall patient-reported quality of life outcomes)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Latanaprost 0.005% once daily (n=231)B. Placebo (n=230)
vs.
end of study
Mean
p value
Within Arm ComparisonsNet Comparisons
A. Latanaprost 0.005% once daily (n=231)B. Placebo (n=230)
vs.